[go: up one dir, main page]

NO942300L - Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin - Google Patents

Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin

Info

Publication number
NO942300L
NO942300L NO942300A NO942300A NO942300L NO 942300 L NO942300 L NO 942300L NO 942300 A NO942300 A NO 942300A NO 942300 A NO942300 A NO 942300A NO 942300 L NO942300 L NO 942300L
Authority
NO
Norway
Prior art keywords
histidine
growth hormone
pharmaceutical preparation
stabilized pharmaceutical
derivative
Prior art date
Application number
NO942300A
Other languages
English (en)
Other versions
NO942300D0 (no
Inventor
Hans Holmegaard Soerensen
Lars Skriver
Annie Rassing Hoelgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942300D0 publication Critical patent/NO942300D0/no
Publication of NO942300L publication Critical patent/NO942300L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO942300A 1991-12-20 1994-06-17 Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin NO942300L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and histidine

Publications (2)

Publication Number Publication Date
NO942300D0 NO942300D0 (no) 1994-06-17
NO942300L true NO942300L (no) 1994-08-19

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942300A NO942300L (no) 1991-12-20 1994-06-17 Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin

Country Status (24)

Country Link
EP (2) EP1197222B1 (no)
JP (2) JP2950617B2 (no)
KR (1) KR100266502B1 (no)
AT (2) ATE368472T1 (no)
AU (1) AU667503B2 (no)
BG (1) BG63075B1 (no)
CA (1) CA2125855C (no)
CZ (1) CZ283361B6 (no)
DE (3) DE69232847T2 (no)
DK (1) DK0618807T3 (no)
ES (2) ES2185625T3 (no)
FI (1) FI115116B (no)
HU (1) HUT69402A (no)
IL (1) IL104152A (no)
MX (1) MX9207374A (no)
NL (1) NL300126I1 (no)
NO (1) NO942300L (no)
NZ (1) NZ246556A (no)
PT (1) PT618807E (no)
RO (1) RO111990B1 (no)
RU (1) RU2122426C1 (no)
SK (1) SK279641B6 (no)
UA (1) UA41502C2 (no)
WO (1) WO1993012812A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
ATE184798T1 (de) * 1994-06-17 1999-10-15 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
TW426737B (en) * 1994-06-27 2001-03-21 Hayashibara Biochem Lab Saccharide composition with reduced reducibility, and preparation and uses thereof
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
KR19980701351A (ko) * 1995-01-13 1998-05-15 슈타르 피아 성장호르몬 및 Ｘ-Ｌｙｓ를 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND X-Lys
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
WO1999024071A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
WO2002000261A2 (en) 2000-06-26 2002-01-03 Monsanto Technology Llc Surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
CN100591212C (zh) 2001-05-18 2010-02-24 丹尼斯科有限公司 改善生面团和面包质量的方法
JP2006523609A (ja) * 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
CA2512052C (en) 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
PL1776455T3 (pl) 2004-07-16 2015-09-30 Dupont Nutrition Biosci Aps Enzym lipolityczny, jego zastosowania w przemyśle spożywczym
JP5201992B2 (ja) * 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ（パブリツク） ケラチノサイト増殖因子の治療用製剤
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
KR20080038391A (ko) * 2005-08-30 2008-05-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페그화 성장 호르몬의 액체 제제
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
WO2008003750A2 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
EP2120869A2 (en) * 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
RU2540922C2 (ru) 2008-10-30 2015-02-10 Ново Нордиск А/С Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
CA3040973A1 (en) * 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
MX2012006980A (es) 2009-12-21 2012-07-17 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos.
CN103119056B (zh) * 2010-09-21 2015-11-25 辉凌公司 用于制备重组人生长激素的改良方法
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN108367094B (zh) * 2015-12-10 2021-09-14 株式会社目立康 肽组合物
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3801605A4 (en) * 2018-05-25 2022-03-16 Dr. Reddy's Laboratories Ltd. STABLE FUSION PROTEIN FORMULATION
KR20210024082A (ko) * 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
RS64438B1 (sr) 2018-10-26 2023-09-29 Novo Nordisk As Stabilne kompozicije semaglutida i njihova upotreba
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DK168790D0 (no) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
CA2125855C (en) 2008-05-13
CZ283361B6 (cs) 1998-03-18
FI942906A0 (fi) 1994-06-17
AU3344693A (en) 1993-07-28
FI115116B (fi) 2005-03-15
UA41502C2 (uk) 2001-09-17
ATE227583T1 (de) 2002-11-15
NL300126I1 (nl) 2003-07-01
EP1197222A2 (en) 2002-04-17
DE69232847T2 (de) 2003-09-11
HUT69402A (en) 1995-09-28
FI942906A (fi) 1994-06-17
DE10399015I2 (de) 2008-08-07
RO111990B1 (ro) 1997-04-30
RU2122426C1 (ru) 1998-11-27
DE10399015I1 (de) 2012-05-03
DK0618807T3 (da) 2003-03-03
CZ150794A3 (en) 1995-01-18
WO1993012812A1 (en) 1993-07-08
HU9401832D0 (en) 1994-09-28
DE69233704T2 (de) 2008-05-21
NO942300D0 (no) 1994-06-17
ES2291264T3 (es) 2008-03-01
IL104152A0 (en) 1993-05-13
EP1197222B1 (en) 2007-08-01
PT618807E (pt) 2003-03-31
KR100266502B1 (ko) 2000-09-15
AU667503B2 (en) 1996-03-28
ATE368472T1 (de) 2007-08-15
BG63075B1 (bg) 2001-03-30
BG98806A (bg) 1995-02-28
JP2950617B2 (ja) 1999-09-20
MX9207374A (es) 1993-07-01
CA2125855A1 (en) 1993-07-08
SK279641B6 (sk) 1999-01-11
RU94045932A (ru) 1997-04-20
IL104152A (en) 1998-06-15
JPH07502516A (ja) 1995-03-16
JPH11315031A (ja) 1999-11-16
DE69233704D1 (de) 2007-09-13
EP1197222A3 (en) 2004-02-04
SK75494A3 (en) 1995-03-08
DE69232847D1 (de) 2002-12-19
NZ246556A (en) 1996-03-26
EP0618807A1 (en) 1994-10-12
ES2185625T3 (es) 2003-05-01
EP0618807B1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
NO942300L (no) Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin
NO942299D0 (no) Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin
FI101194B1 (fi) Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmistamiseksi
ZA958604B (en) A pharmaceutical formulation
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
MX9800309A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento y un peptido que comprende al menos un residuo de aminoacido basico y al menos un residuo de aminoacido acido.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application